{"id":"W2623725180","doi":"10.1016/s1470-2045(17)30339-x","title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; Shionogi; AstraZeneca; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Eli Lilly and Company","keywords":"Ceritinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; ALK inhibitor; Internal medicine; Chemotherapy; Oncology; Docetaxel; Pemetrexed; Gastroenterology; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005353074,0.000284415,0.001357203,0.00005401842,0.0003321462,0.0001076257,0.0004219557,0.000139019,0.0001817426],"category_scores_gemma":[0.00007924026,0.0001696143,0.00006359263,0.00006837053,0.0002177148,0.0001329887,0.00006758898,0.0002747787,0.000003323039],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002794537,"about_ca_system_score_gemma":0.0005413057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008576998,"about_ca_topic_score_gemma":0.001133105,"domain_scores_codex":[0.9983894,0.0001773786,0.0003723526,0.0004106437,0.0001751844,0.0004750034],"domain_scores_gemma":[0.998349,0.0002817703,0.0004563984,0.0006519094,0.0001256746,0.0001352317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9393207,0.003042432,0.02021008,0.00007383629,0.0009590885,0.00003108732,0.002250622,0.000001448145,0.0001488185,0.00001233337,0.004122496,0.02982705],"study_design_scores_gemma":[0.9631067,0.006986218,0.01318767,0.0001386486,0.0006674747,0.000002782725,0.0001026312,0.0000950685,0.00009492955,0.00001090322,0.01541561,0.0001914008],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9619135,0.0006901593,0.00001527056,0.008796905,0.0005643225,0.01096955,0.00006133995,0.00002805908,0.01696088],"genre_scores_gemma":[0.9910239,0.001594936,0.0006561208,0.002203633,0.0007178829,0.002614627,0.00004700763,0.00006047343,0.001081427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02963565,"threshold_uncertainty_score":0.6916672,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04534884463340635,"score_gpt":0.4133336191056075,"score_spread":0.3679847744722012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}